Pharmaceutical 3D printing has been in the focus of research projects for almost a decade. Still, the translation to clinical application is impeded. And while several reasons can be identified for the slow translation, the identification of use cases is a critical one. Potentially higher costs have to be offset with added value in terms of quality of life or survival. This presentation will discuss research projects that aim to improve pharmaceutical treatment of two undertreated groups – children in oncological care and veterinary patients.
 | 30-31 January 2025 |  |
|||||
Also the necessary steps to implement 3D printing in hospital and veterinary pharmacies will be outlined and discussed.
This is presented by Julian Quodbach, Assistant Professor at Utrecht University.
The lack of proper medication for a significant number of patients, be it with regard to dosages, size, or taste, is what Julian drives. that includes the Undertreated Patients in Pediatric Oncology Veterinary Care as well. In the short run he sees a further exploration of new technologies, e.g., volumetric printing. In the long run it will be on oral delivery of certain biological molecules, process robustness and maturation of the technology.
About Julian Quodbach
Julian is a pharmacist by training and received his PhD from the University of Düsseldorf, Germany. Since 2015, he is investigating the pharmaceutical applications of different 3D printing technologies, focusing primarily on extrusion-based technologies. In January 2022, he transitioned to Utrecht University. There, his focus shifted to powder-based technologies, especially selective laser sintering. Together with different academic research hospitals, he promotes the translation of 3D printing to clinical applications to help improve medical therapies.
About Utrecht University, department of Pharmaceutics
The Advanced Drug Delivery and Drug Targeting Program of the department of Pharmaceutics aims at providing new strategies to solve delivery problems encountered by pharmacologically active compounds.
The core activity of the department is the design and pre-clinical testing of tailor-made drug delivery systems for site-specific, time- and/or rate-controlled delivery of small molecular weight drugs, therapeutic proteins, nucleic acids (including DNA and siRNA), and antigens for therapy and prevention of life-threatening diseases such as cancer, inflammation and infectious diseases. The combination of complementary fields of expertise brought together in the research program is unique. It allows the development of novel drug delivery systems from scratch up to the preclinical testing phase. The department of Pharmaceutics has intensive collaborations with academic, industrial, and governmental groups.
For more information, visit the website.
Julian Quodbach will speak at the 2023 edition of the 3D Medical Conference.
.